The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Preceding infections, immune factors, and outcome in Guillain–Barré syndrome
Abstract
OBJECTIVE: To test the hypothesis that different preceding infections influence the neurophysiologic classification and clinical features of Guillain-Barré syndrome (GBS). METHODS: We tested pretreatment sera, 7 +/- 3 (mean +/- SD) days from onset, from 229 patients with GBS in a multicenter trial of plasma exchange and immunoglobulin, for serological markers of infection, adhesion molecules, and cytokine receptors, and compared these with neurophysiologic and clinical features. RESULTS: Recent infection by Campylobacter jejuni was found in 53 patients (23%), cytomegalovirus in 19 (8%), and Epstein-Barr virus in four (2%). Patients with C. jejuni infection were more likely than others to have neurophysiologic criteria of axonal neuropathy or inexcitable nerves, antiganglioside GM(1) antibodies, pure motor GBS, lower CSF protein, and worse outcome. Patients with cytomegalovirus infection were younger and more likely than others to have raised serum concentrations of molecules important in T lymphocyte activation and migration, soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble leukocyte selectin, and soluble interleukin-2 receptor (sIL-2R). Concentrations of sICAM-1 and soluble tumor necrosis factor receptor were higher in patients with inexcitable nerves than those with demyelinating neurophysiology. Logistic regression analysis showed death or inability to walk unaided at 48 weeks were associated with diarrhea, inexcitable nerves, severe arm weakness, age over 50, raised sIL-2R concentration and absence of immunoglobulin (Ig) M antiganglioside GM(1) antibodies. CONCLUSIONS: Subtypes of GBS defined by preceding infections were only approximately associated with different patterns of clinical, neurophysiologic, and immunologic features. A single infectious agent caused more than one type of pathology in GBS, implying interaction with additional host factors. Most patients had no identified infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Electrophysiological classification of guillain‐barré syndrome: Clinical associations and outcome
Hadden, R. D. M., Cornblath, D. R., Hughes, R. A. C., Zielasek, J., Hartung, H. ‐., Toyka, K. V., Swan, A. V., & The Plasma Exchange/Sandoglobulin Guillain‐Barré Syndrome Trial Group (1998) · Annals of Neurology · doi:10.1002/ana.410440512 · Cited by 942
Self-citationThe spectrum of antecedent infections in Guillain-Barré syndrome: A case-control study
Jacobs, B. C., Rothbarth, P. H., van der Meché, F. G. A., Herbrink, P., Schmitz, P. I. M., de Klerk, M. A., & van Doorn, P. A. (1998) · Neurology · doi:10.1212/wnl.51.4.1110 · Cited by 826
Ho, T. W., Mishu, B., Li, C. Y., Gao, C. Y., Cornblath, D. R., Griffin, J. W., Asbury, A. K., Blaser, M. J., & McKhann, G. M. (1995) · Brain · doi:10.1093/brain/118.3.597 · Cited by 764
Self-citationCampylobacter jejuni Infection and Guillain–Barré Syndrome
Rees, J. H., Soudain, S. E., Gregson, N. A., & Hughes, R. A. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511233332102 · Cited by 753
Self-citation(1997) · The Lancet · doi:10.1016/s0140-6736(96)09095-2 · Cited by 733
(1997) · Transfusion Medicine Reviews · doi:10.1016/s0887-7963(97)80059-4 · Cited by 610
Six widespread bacterial clones among Escherichia coli K1 isolates
Achtman, M., Mercer, A., Kusecek, B., Pohl, A., Heuzenroeder, M., Aaronson, W., Sutton, A., & Silver, R. P. (1983) · Infection and Immunity · doi:10.1128/iai.39.1.315-335.1983 · Cited by 447
Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barr� syndrome
Ho, T. W., Willison, H. J., Nachamkin, I., Li, C. Y., Veitch, J., Ung, H., Wang, G. R., Liu, R. C., Cornblath, D. R., Asbury, A. K., et al. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199902)45:2<168::aid-ana6>3.0.co;2-6 · Cited by 329
Self-citationCampylobacter jejuni infections and anti‐GM1 antibodies in guillain‐barré syndrome
Jacobs, B. C., van Doorn, P. A., Tio‐Gillen, A. P., Visser, L. H., van der Meché, F. G. A., Schmitz, P. I. M., Herbrink, P., & Hooijkaas, H. (1996) · Annals of Neurology · doi:10.1002/ana.410400209 · Cited by 314
A prospective study of acute idiopathic neuropathy. I. Clinical features and their prognostic value.
Winer, J. B., Hughes, R. A., & Osmond, C. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.5.605 · Cited by 297
Self-citationImmunopathogenesis and treatment of the guillain‐barré syndrome—part I
Hartung, H., Toyka, K. V., Pollard, J. D., & Harvey, G. K. (1995) · Muscle & Nerve · doi:10.1002/mus.880180202 · Cited by 288
Self-citationA prospective study of acute idiopathic neuropathy. II. Antecedent events.
Winer, J. B., Hughes, R. A., Anderson, M. J., Jones, D. M., Kangro, H., & Watkins, R. P. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.5.613 · Cited by 284
Self-citationMcKhann, G. M., Griffin, J. W., Cornblath, D. R., Mellits, E. D., Fisher, R. S., Quaskey, S. A., & The Guillain‐Barré Syndrome Study Group (1988) · Annals of Neurology · doi:10.1002/ana.410230406 · Cited by 275
Self-citationRees, J. H., Gregson, N. A., & Hughes, R. A. C. (1995) · Annals of Neurology · doi:10.1002/ana.410380516 · Cited by 266
Self-citationVisser, L. H., van der Meche, F. G. A., Meulstee, J., Rothbarth, P., Jacobs, B. C., Schmitz, P. I. M., & van Doorn, P. A. (1996) · Neurology · doi:10.1212/wnl.47.3.668 · Cited by 224
Mishu, B., Ilyas, A. A., Koski, C. L., Vriesendorp, F., Cook, S. D., Mithen, F. A., & Blaser, M. J. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-12-199306150-00006 · Cited by 184
Visser, L. H., Van Der Meché, F. G. A., Van Doorn, P. A., Meulstee, J., Jacobs, B. C., Oomes, P. G., & Kleyweg, R. P. (1995) · Brain · doi:10.1093/brain/118.4.841 · Cited by 177
Enders, U., Karch, H., Toyka, K. V., Michels, M., Zielasek, J., Pette, M., Heesemann, J., & Hartung, H. (1993) · Annals of Neurology · doi:10.1002/ana.410340208 · Cited by 171
Self-citationThe distribution of ganglioside-like moieties in peripheral nerves
Sheikh, K. A., Deerinck, T. J., Ellisman, M. H., & Griffin, J. W. (1999) · Brain · doi:10.1093/brain/122.3.449 · Cited by 145
Campylobacter jejuni lipopolysaccharides in Guillain-Barre syndrome
Sheikh, K. A., Nachamkin, I., Ho, T. W., Willison, H. J., Veitch, J., Ung, H., Nicholson, M. A., Li, C. Y., Wu, H., Shen, B., et al. (1998) · Neurology · doi:10.1212/wnl.51.2.371 · Cited by 135
Self-citationPrognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange
Visser, L. H., Schmitz, P. I. M., Meulstee, J., van Doorn, P. A., & van der Meché, F. G. A. (1999) · Neurology · doi:10.1212/wnl.53.3.598 · Cited by 115
Circulating adhesion molecules and inflammatory mediators in demyelination: A review
Hartung, H.-P., Archelos, J. J., Zielasek, J., Gold, R., Koltzenburg, M., Reiners, K., & Toyka, K. V. (1995) · Neurology · doi:10.1212/wnl.45.6_suppl_6.s22 · Cited by 112
Self-citationHao, Q., Saida, T., Kuroki, S., Nishimura, M., Nukina, M., Obayashi, H., & Saida, K. (1998) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(97)00166-5 · Cited by 106
Two patterns of clinical recovery in Guillain-Barré syndrome with IgG anti-GM1 antibody
Kuwabara, S., Asahina, M., Koga, M., Mori, M., Yuki, N., & Hattori, T. (1998) · Neurology · doi:10.1212/wnl.51.6.1656 · Cited by 102
Mechanisms of Immune Regulation in the Peripheral Nervous System
Gold, R., Archelos, J. J., & Hartung, H. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00231.x · Cited by 95
Self-citationKoga, M., Yuki, N., Takahashi, M., SAITO, K., & Hirata, K. (1998) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(97)00168-9 · Cited by 95
Cytomegalovirus infections and anti-GM2 antibodies in Guillain-Barre syndrome.
Jacobs, B. C., van Doorn, P. A., Groeneveld, J. H., Tio‐Gillen, A. P., & van der Meché, F. G. A. (1997) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.62.6.641 · Cited by 91
Yuki, N., Ho, T. W., Tagawa, Y., Koga, M., Li, C. Y., Hirata, K., & Griffin, J. W. (1999) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(99)00056-8 · Cited by 87
Antiganglioside antibodies in Guillain-Barre syndrome after a recent cytomegalovirus infection
Khalili-Shirazi, A., Gregson, N. A., Gray, I. A., Rees, J. H., Winer, J. B., & Hughes, R. A. (1999) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.3.376 · Cited by 86
Self-citationAcute cytomegalovirus infection and IgM anti-GM2 antibody
Yuki, N., & Tagawa, Y. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(97)00174-3 · Cited by 69
Risk factors for treatment related clinical fluctuations in Guillain-Barre syndrome
Visser, L. E., van der Meché, F., Meulstee, J., van Doorn, P. A., & the Dutch Guillain-Barre study group (1998) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.64.2.242 · Cited by 66
Self-citationSharief, M. K., Ingram, D. A., & Swash, M. (1997) · Annals of Neurology · doi:10.1002/ana.410420112 · Cited by 50
Cann, S. A. H., Netten, J. P. V., & Netten, C. V. (2000) · Pure Amsterdam UMC · doi:10.1002/1531-8249(200003)47:3
Cited by
Hughes, R. A., & Cornblath, D. R. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67665-9 · Cited by 1,676
Self-citationWillison, H. J., Jacobs, B. C., & van Doorn, P. A. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00339-1 · Cited by 1,609
Yuki, N., & Hartung, H.-P. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1114525 · Cited by 1,260
Self-citationGuillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis
van den Berg, B., Walgaard, C., Drenthen, J., Fokke, C., Jacobs, B. C., & van Doorn, P. A. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.121 · Cited by 1,101
Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome
van Doorn, P. A., Ruts, L., & Jacobs, B. C. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70215-1 · Cited by 828
Metadata
- Authors
- Hadden, R. D. M., Karch, H., Hartung, H.-P., Zielasek, J., Weissbrich, B., Schubert, J., Weishaupt, A., Cornblath, D. R., Swan, A. V., Hughes, R. A. C., Toyka, K. V., & the Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group*
- Venue
- Neurology
- Published
- 2001-03-27
- Volume
- 56
- Issue
- 6
- Pages
- 758-765
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W1986245753
- Cited by
- 375
- References
- 33
- FWCI
- 9.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.